Skip to main content
    Poison Phenibut

    An independent public-health evidence base on phenibut

    In an emergency

    For clinicians

    Phenibut: recognition and the management literature

    This page summarises published literature for clinician awareness. It is not clinical guidance, and it is not a protocol. There is no consensus guideline for phenibut withdrawal.[11] Every management statement below is a report of what was described in a specific publication, carries an inline citation, and should be read as such. For case-specific advice, your regional poison center is staffed by medical toxicologists at all hours: 1-800-222-1222.

    1

    Recognition

    Phenibut does not appear on standard urine drug screens or routine toxicology panels. A negative screen does not exclude it, and in published cases a screen that was negative — or positive only for an unrelated substance the patient used legitimately — actively delayed the diagnosis.[7,10]

    The presentation that should raise the question is an agitated delirium of unclear origin, particularly one that does not settle with benzodiazepines and antipsychotics as expected.[7,10] In one published case, escalating intravenous benzodiazepine over a quarter of an hour had minimal effect and the patient was intubated for airway protection.[10] In another, benzodiazepines and antipsychotics were ineffective and the cause emerged only when a family member found the product at home and a poison center was consulted.[7]

    The history is frequently not volunteered. Patients who bought a “supplement” or a “nootropic” online often do not classify it as a drug, and will answer a question about drug use honestly in the negative.[5]

    2

    Pharmacology relevant to management

    Phenibut is β-phenyl-γ-aminobutyric acid: a GABA analogue with a phenyl ring that confers blood-brain barrier penetration. It acts primarily as a GABA-B agonist, structurally and pharmacologically related to baclofen, with some GABA-A activity.[4]

    Two implications follow. Withdrawal phenomenology resembles benzodiazepine and alcohol withdrawal, which is why it is mistaken for both. And because the primary target is GABA-B rather than GABA-A, benzodiazepines — which act at GABA-A — are not pharmacologically matched to the receptor being withdrawn from, which is one proposed explanation for the incomplete or paradoxical responses described in the case literature.[8,11]

    3

    What the literature describes for management

    The following are reported approaches from individual publications, presented as a literature summary. They are not recommendations, not a protocol, and not a substitute for consultation. No dosing is given anywhere on this site.

    Baclofen as a receptor-matched substitute

    Several published cases describe baclofen — a GABA-B agonist — being used as a substitution agent during phenibut withdrawal, with subsequent reduction. In one case the patient became fully oriented and linear in thinking by the ninth hospital day on this approach.[7,8,11]

    Benzodiazepines

    Benzodiazepines are widely used in reported cases, with mixed results. One report describes diazepam appearing to worsen the patient’s condition before baclofen was substituted.[8] Another describes escalating benzodiazepines being ineffective as monotherapy, and forming part of a combination alongside baclofen, antipsychotics, and beta-blockers.[7]

    Supportive and intensive care

    Reported acute presentations have required airway protection and mechanical ventilation, and review literature describes central nervous system depression, coma, and respiratory depression among the toxic effects, with monitoring in an intensive care setting recommended where consciousness is impaired.[10,12]

    The state of the evidence

    A 2023 systematic review of phenibut withdrawal screened several hundred articles and included 25, all of which were case reports or published conference abstracts. There are no controlled trials, and no established consensus guideline for management exists.[11]

    4

    Published cases

    Summarised in our own words, each with a retrievable citation. Single case reports unless stated otherwise.

    Tolerance can develop within weeks, and dependence with it[9]

    A man in his twenties presented to an emergency department asking for help with detoxification. He had begun using phenibut bought online roughly a month earlier while also drinking heavily, and had found that the amount that once worked stopped working — the report notes that tolerance to phenibut has been described as developing within one to two weeks. When he tried to stop on his own he developed cold sweats, anxiety, insomnia, and both visual and auditory hallucinations. His clinicians described a withdrawal that resembled alcohol withdrawal but ran longer and more severely than his drinking alone would explain, and concluded that phenibut dependence was adding to it. He was managed with benzodiazepines for the acute withdrawal alongside psychiatric medication for anxiety and protracted symptoms.

    A single published case report. It describes what happened to one patient; it does not establish how often this happens.

    Withdrawal can present as an agitated delirium that standard treatment does not touch[7]

    A woman in her fifties was brought to an emergency department with severe psychomotor agitation, disorganised thinking, visual hallucinations, and a complete inability to sleep. Her partner reported that the movement disturbance and fluctuating alertness had come on suddenly that morning. Her urine toxicology screen showed only benzodiazepines, which she used legitimately, and her presentation was initially read as a primary psychiatric episode. Benzodiazepines and antipsychotics did not work. The cause only became clear when her partner found phenibut at home and a poison centre was called; her symptoms had begun about three days after she stopped taking it, following months of regular use. She was treated with baclofen as a substitute at the same receptor, along with escalating benzodiazepines, antipsychotics chosen with cardiac monitoring in mind, and beta-blockers for blood-pressure and heart-rate instability. She was in hospital for roughly three and a half weeks, and her psychotic symptoms resolved by the fourth week.

    A single published case report. Its value here is diagnostic: it documents a presentation that was missed precisely because the drug does not appear on a standard screen.

    Withdrawal can outlast the hospital stay, and benzodiazepines can make it worse[8]

    A man in his thirties was admitted after a suicide attempt. He had been buying phenibut from internet vendors and escalating his use over a period of weeks, and described a dream-like, out-of-body state along with several days without sleep. On arrival he was tachycardic with dilated pupils and flushed skin, and although he remained oriented, his thinking was tangential and illogical. Withdrawal began on his second hospital day and brought agitation, disorientation, visual hallucinations, and tremor that lasted about a week. Notably, treatment with diazepam appeared to worsen rather than settle his condition; he was subsequently managed with baclofen and was clear-thinking and fully oriented by the ninth day.

    A single published case report. The paradoxical response to a benzodiazepine is one observation in one patient, not an established pharmacological rule.

    Acute presentations can require airway protection and intensive care[10]

    A man in his thirties with a history of polysubstance use was brought in by ambulance after being found at home behaving incoherently. He arrived agitated, confused, and resistant to care, with a Glasgow Coma Scale score in the mildly impaired range. Repeated intravenous lorazepam over a quarter of an hour had minimal effect, and he was intubated and mechanically ventilated because he could not cooperate with care safely. His urine screen was positive for benzodiazepines and cannabinoids; ethanol, salicylate, acetaminophen, and ammonia were all below detection, and his bloodwork showed a raised white cell count, lactic acidosis, and an elevated anion gap. He was admitted to intensive care, extubated two days later, and discharged home after psychiatric consultation.

    A single published case report. Broader poison-centre and review literature describes central nervous system depression, coma, and respiratory depression requiring intubation in phenibut cases, particularly alongside other depressants.

    5

    What to ask the patient

    The questions that surface this history are the ones that do not use the word “drug.”

    • Are you taking any supplements, powders, or capsules bought online or from a smoke shop or vape shop?
    • Anything sold as a “nootropic,” a “cognitive enhancer,” a “mood booster,” or a sleep aid?
    • Anything you measure out yourself at home, from a bag or a tub, rather than take from a labelled bottle?
    • Anything you take every day for anxiety or for sleep that a doctor did not prescribe?
    • When did you last take it — and have you stopped or cut down in the last week?

    Where the patient cannot give a history, asking a family member to look for containers at home has been the step that resolved the diagnosis in at least one published case.[7]

    Reading this because of a specific person? Practical guidance on stopping phenibut is written for them rather than for a professional audience. Poison Control (1-800-222-1222) advises the public and clinicians alike, at no cost, at any hour.

    6

    Reporting

    Report phenibut cases to your regional poison center: 1-800-222-1222 reaches it from anywhere in the United States.

    This is worth the five minutes for a reason that is visible on this site. The only national surveillance series on phenibut is built from poison-center calls, it ends in 2019, and §3 of the dossier spends several paragraphs explaining how incomplete it is.[1] That incompleteness is not fixable by anyone except the clinicians who see these cases. A case you report becomes data someone can cite; a case you do not report is invisible to every argument made about this compound.

    7

    References

    Provenance

    Published
    Last reviewed
    Clinical review
    None. This content is compiled from the cited public sources and has not undergone independent clinical review.

    Cite this page

    Poison Phenibut. "Phenibut for clinicians: recognition and the management literature." https://poisonphenibut.com/for-clinicians (last reviewed September 8, 2026).

    See About & editorial policy for how this site is written, reviewed, and corrected, and the disclaimer for what it is and is not.